cyclin-dependent kinase


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

cyclin-dependent kinase

[¦sī·klin di¦pen·dənt ′kī‚nās]
(cell and molecular biology)
A family of kinases that, once activated by cyclin, regulate the cell cycle by adding phosphate groups to a variety of protein substrates that control processes in the cycle. Abbreviated Cdk.
References in periodicals archive ?
Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related Endometrial adenocarcinomas.
Overexpression of cyclin-dependent kinase inhibitor 1 (WAF1) from the kinase inhibitor protein group and PAK-[gamma] (p21- activated kinase [gamma]), combined with overexpression of CDKN2D (p19-INK4D) and cell division protein kinase 3 (CDK3), denote a major derangement in the regulation of cell-cycle progression.
Dinaciclib is a pro-apoptotic inhibitor of cyclin-dependent kinases being evaluated by Merck for the potential treatment of cancer.
2] Genes: Cdkn2a, cyclin-dependent kinase inhibitor 2A [Mus musculus gene]; Cdkn2b, cyclin-dependent kinase inhibitor 2B [Mus musculus gene]; CDKN2A, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) [human gene]; CDKN2BB, cyclin-dependent kinase inhibitor 2B (melanoma, p16, inhibits CDK4) [human gene].
kip1]: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.
They developed a screening test to determine what controlled the activity of a cyclin-dependent kinase enzyme.
RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis.
Indianapolis, Indiana-based global pharmaceuticals specialist Eli Lilly and Company's (NYSE: LLY) Phase 3 JUNIPER study evaluating Verzenio (abemaciclib), a cyclin-dependent kinase 4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS), the company said.
Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).
18 SCIENCE, a team led by James Roberts of the Fred Hutchinson Cancer Research Center in Seattle reports that human cells about to copy their genes have high levels of two proteins -- cyclin E and cyclin-dependent kinase 2.